Benjamin Bowe1,2,3, Yan Xie1,2,3, Evan Xu1,4, Ziyad Al-Aly5,3,6,7,8. 1. Clinical Epidemiology Center, Research and Development Service, Veterans Affairs Saint Louis Health Care System, Saint Louis, Missouri. 2. Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, Saint Louis, Missouri. 3. Veterans Research and Education Foundation of Saint Louis, Saint Louis, Missouri. 4. Saint Louis University School of Medicine, Saint Louis, Missouri. 5. Clinical Epidemiology Center, Research and Development Service, Veterans Affairs Saint Louis Health Care System, Saint Louis, Missouri zalaly@gmail.com. 6. Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri. 7. Nephrology Section, Medicine Service, Veterans Affairs Saint Louis Health Care System, Saint Louis, Missouri. 8. Institute for Public Health, Washington University in Saint Louis, Saint Louis, Missouri.
Abstract
BACKGROUND: COVID-19 is associated with increased risk of post-acute sequelae involving pulmonary and extrapulmonary organ systems-referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. METHODS: We built a cohort of 1,726,683 US Veterans identified from March 1, 2020 to March 15, 2021, including 89,216 patients who were 30-day survivors of COVID-19 and 1,637,467 non-infected controls. We examined risks of AKI, eGFR decline, ESKD, and major adverse kidney events (MAKE). MAKE was defined as eGFR decline ≥50%, ESKD, or all-cause mortality. We used inverse probability-weighted survival regression, adjusting for predefined demographic and health characteristics, and algorithmically selected high-dimensional covariates, including diagnoses, medications, and laboratory tests. Linear mixed models characterized intra-individual eGFR trajectory. RESULTS: Beyond the acute illness, 30-day survivors of COVID-19 exhibited a higher risk of AKI (aHR, 1.94; 95% CI, 1.86 to 2.04), eGFR decline ≥30% (aHR, 1.25; 95% CI, 1.14 to 1.37), eGFR decline ≥40% (aHR, 1.44; 95% CI, 1.37 to 1.51), eGFR decline ≥50% (aHR, 1.62; 95% CI, 1.51 to 1.74), ESKD (aHR, 2.96; 95% CI, 2.49 to 3.51), and MAKE (aHR, 1.66; 95% CI, 1.58 to 1.74). Increase in risks of post-acute kidney outcomes was graded according to the severity of the acute infection (whether patients were non-hospitalized, hospitalized, or admitted to intensive care). Compared with non-infected controls, 30-day survivors of COVID-19 exhibited excess eGFR decline (95% CI) of -3.26 (-3.58 to -2.94), -5.20 (-6.24 to -4.16), and -7.69 (-8.27 to -7.12) ml/min per 1.73 m2 per year, respectively, in non-hospitalized, hospitalized, and those admitted to intensive care during the acute phase of COVID-19 infection. CONCLUSIONS: Patients who survived COVID-19 exhibited increased risk of kidney outcomes in the post-acute phase of the disease. Post-acute COVID-19 care should include attention to kidney disease.
BACKGROUND: COVID-19 is associated with increased risk of post-acute sequelae involving pulmonary and extrapulmonary organ systems-referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. METHODS: We built a cohort of 1,726,683 US Veterans identified from March 1, 2020 to March 15, 2021, including 89,216 patients who were 30-day survivors of COVID-19 and 1,637,467 non-infected controls. We examined risks of AKI, eGFR decline, ESKD, and major adverse kidney events (MAKE). MAKE was defined as eGFR decline ≥50%, ESKD, or all-cause mortality. We used inverse probability-weighted survival regression, adjusting for predefined demographic and health characteristics, and algorithmically selected high-dimensional covariates, including diagnoses, medications, and laboratory tests. Linear mixed models characterized intra-individual eGFR trajectory. RESULTS: Beyond the acute illness, 30-day survivors of COVID-19 exhibited a higher risk of AKI (aHR, 1.94; 95% CI, 1.86 to 2.04), eGFR decline ≥30% (aHR, 1.25; 95% CI, 1.14 to 1.37), eGFR decline ≥40% (aHR, 1.44; 95% CI, 1.37 to 1.51), eGFR decline ≥50% (aHR, 1.62; 95% CI, 1.51 to 1.74), ESKD (aHR, 2.96; 95% CI, 2.49 to 3.51), and MAKE (aHR, 1.66; 95% CI, 1.58 to 1.74). Increase in risks of post-acute kidney outcomes was graded according to the severity of the acute infection (whether patients were non-hospitalized, hospitalized, or admitted to intensive care). Compared with non-infected controls, 30-day survivors of COVID-19 exhibited excess eGFR decline (95% CI) of -3.26 (-3.58 to -2.94), -5.20 (-6.24 to -4.16), and -7.69 (-8.27 to -7.12) ml/min per 1.73 m2 per year, respectively, in non-hospitalized, hospitalized, and those admitted to intensive care during the acute phase of COVID-19 infection. CONCLUSIONS: Patients who survived COVID-19 exhibited increased risk of kidney outcomes in the post-acute phase of the disease. Post-acute COVID-19 care should include attention to kidney disease.
Authors: Charles E Leonard; Cristin P Freeman; Craig W Newcomb; Peter P Reese; Maximilian Herlim; Warren B Bilker; Sean Hennessy; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2012-08-09 Impact factor: 2.890
Authors: Sarah E Daugherty; Yinglong Guo; Kevin Heath; Micah C Dasmariñas; Karol Giuseppe Jubilo; Jirapat Samranvedhya; Marc Lipsitch; Ken Cohen Journal: BMJ Date: 2021-05-19
Authors: Benjamin Bowe; Miao Cai; Yan Xie; Andrew K Gibson; Geetha Maddukuri; Ziyad Al-Aly Journal: Clin J Am Soc Nephrol Date: 2020-11-16 Impact factor: 8.237
Authors: Yan Xie; Benjamin Bowe; Andrew K Gibson; Janet B McGill; Geetha Maddukuri; Ziyad Al-Aly Journal: JAMA Intern Med Date: 2021-08-01 Impact factor: 21.873
Authors: Meryl Waldman; Maria Jose Soler; Clara García-Carro; Liz Lightstone; Tabitha Turner-Stokes; Megan Griffith; Joan Torras; Laura Martinez Valenzuela; Oriol Bestard; Colin Geddes; Oliver Flossmann; Kelly L Budge; Chiara Cantarelli; Enrico Fiaccadori; Marco Delsante; Enrique Morales; Eduardo Gutierrez; Jose A Niño-Cruz; Armando J Martinez-Rueda; Giorgia Comai; Claudia Bini; Gaetano La Manna; Maria F Slon; Joaquin Manrique; Alejandro Avello; Raul Fernandez-Prado; Alberto Ortiz; Smaragdi Marinaki; Carmen Rita Martin Varas; Cristina Rabasco Ruiz; Milagros Sierra-Carpio; Rebeca García-Agudo; Gema Fernández Juárez; Alexander J Hamilton; Annette Bruchfeld; Constantina Chrysochou; Lilian Howard; Smeeta Sinha; Tim Leach; Irene Agraz Pamplona; Umberto Maggiore; Paolo Cravedi Journal: Kidney360 Date: 2021-12-03
Authors: Erin O Wissler Gerdes; Greg Vanichkachorn; Brandon P Verdoorn; Gregory J Hanson; Avni Y Joshi; M Hassan Murad; Stacey A Rizza; Ryan T Hurt; Tamar Tchkonia; James L Kirkland Journal: Transl Res Date: 2021-10-22 Impact factor: 7.012